BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Grasping Various Kinds of Local misdemeanors - 2Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- 3Startled Venezuelans express relief but also fear after Maduro arrest
- 4'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- 5Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- An Aide On Upgrading Your FICO rating
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- China's Normal Ponders: A Visual Excursion
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- Paris Agreement target off the table, report says
